A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)

Completed · Phase 2

Conditions studied: Candidiasis, Vulvovaginal

In brief

The purpose of this study is to determine if the novel oral agent VT-1161 is safe and effective in treating patients with acute vulvovaginal candidiasis (also referred to as yeast infection). VT-1161 has been designed to inhibit CYP51, an enzyme essential for fungal growth. Inhibition of CYP51 results in the accumulation of chemicals know to be toxic to the fungus. CYP51 is the molecular target of the class of drugs referred to as 'azole antifungals'. All currently approved azole drugs have poor selectivity for CYP51 and this results in many of the side effects associated with the azole antifungals. The safety profile of the class similarly limits use in chronic treatment of non-life-threatening fungal infections. VT-1161 has been design to be safer and more active against the fungal species typically responsible for vaginal yeast infections (i.e. vulvovaginal candidiasis).

Key facts

Study ID

NCT01891331

Run by

Viamet

People needed

55

Starts

2013-08-01

Expected to finish

2014-12-01

Last updated by the study team

2018-08-01

Who can join

Age: 18 and older, up to 65. Sex: female. Healthy volunteers: not accepted.

You may not qualify if…

• Evidence of major organ system disease
• History of cervical cancer
• History of diabetes mellitus
• Pregnant
• Recent use of systemic antifungal drugs or systemic antimicrobial therapy for any reason
• Recent use of drugs to treat vaginal infections
• Recent use of immunosuppressive therapies

Where it is running

• Altus Research — Lake Worth, Florida, United States
• Healthcare Clinical Data, Inc — North Miami, Florida, United States
• SUNY Downstate Medical Center — Brooklyn, New York, United States
• Lyndhurst Clinical Research — Raleigh, North Carolina, United States
• Lyndhurst Clinical Research — Winston-Salem, North Carolina, United States
• Drexel Vaginitis Center — Philadelphia, Pennsylvania, United States
• Brownstone Clinical Trials, LLC — Irving, Texas, United States
• Harborview ID Research Clinic — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.